Sermorelin vs Ipamorelin vs Tesamorelin vs CJC-1295: Evidence, Uses, and Safety

Sermorelin, tesamorelin, and CJC-1295 are growth hormone-releasing hormone analogs that signal the pituitary to release growth hormone; ipamorelin works through the ghrelin receptor 1, 2, 8. Tesamorelin has the strongest indication-specific human evidence for HIV-associated lipodystrophy 4, 5. CJC-1295 has limited human trial data, while ipamorelin’s human evidence is sparse 1, 8. Sermorelin is available at Chia after clinician review.

What is the quick difference between sermorelin, ipamorelin, tesamorelin, and CJC-1295?

Sermorelin and tesamorelin are closer cousins: both are growth hormone-releasing hormone analogs. CJC-1295 is also a modified GHRH analog, while ipamorelin is different because it acts at the growth hormone secretagogue receptor, also called GHS-R1a or the ghrelin receptor 1, 2.

In plain English: sermorelin, tesamorelin, and CJC-1295 press the pituitary’s GHRH “release” button. Ipamorelin presses a different button that can also lead to growth hormone pulses. The evidence is not equal across the group: tesamorelin has indication-specific phase 3 evidence, CJC-1295 has smaller human endocrine-marker data, and ipamorelin has limited human outcome evidence.

How does the growth hormone and IGF-1 pathway work?

Growth hormone starts with brain signaling. The hypothalamus sends growth hormone-releasing hormone to the pituitary gland, where somatotroph cells release growth hormone into the blood; growth hormone then signals tissues, including the liver, to make insulin-like growth factor 1, or IGF-1 8.

This matters because stimulating your own growth hormone release is not the same as taking human growth hormone directly. GHRH analogs and ghrelin-receptor agonists depend on a working pituitary gland. They aim to amplify signaling in an existing system, not replace the hormone outright.

IGF-1 is a useful biomarker, but a higher IGF-1 number is not proof of longer life or better health. Human studies can link IGF-1 and IGF-binding proteins to disease and glycemia, but biomarker change alone does not prove anti-aging benefit, muscle gain, or lifespan extension 3.

What is sermorelin, and what does the evidence show?

Sermorelin acetate is often described as GHRH(1-29), a shortened growth hormone-releasing hormone analog. It binds the GHRH receptor on pituitary somatotroph cells and can stimulate growth hormone release when the pituitary can respond 2.

A human randomized study compared synthetic GHRH(1-29NH2) with growth hormone-releasing peptide-2 in children with growth hormone insufficiency or idiopathic short stature; GHRH(1-29NH2) produced growth hormone-releasing effects in that clinical setting 2. That is useful mechanistic evidence, but it does not prove adult longevity, recovery, or body-composition outcomes.

For adult wellness goals, the honest answer is that outcome evidence is limited. Patients may hear sermorelin discussed for sleep, recovery, body composition, or healthy aging, but those uses should be treated as off-label or investigational unless a clinician can point to evidence for that person’s situation.

Safety questions include headache, flushing, injection-site symptoms, swelling, joint discomfort, and possible changes in glucose control. People with diabetes, abnormal glucose control, pituitary disease, active cancer, a cancer history, pregnancy, breastfeeding, or complex endocrine conditions should review risks with a clinician before considering growth hormone pathway therapy 3, 10.

What is ipamorelin, and how is it different?

Ipamorelin, also called NNC 26-0161, is usually described as a growth hormone secretagogue receptor agonist. That means it works through the ghrelin receptor pathway, not the GHRH receptor pathway used by sermorelin, tesamorelin, and CJC-1295 8.

Mechanistically, that difference is why ipamorelin is often discussed alongside GHRH analogs. Two separate signals can affect growth hormone pulse biology. But mechanism is not the same as proof of better human outcomes.

Compared with tesamorelin and CJC-1295, ipamorelin has sparse human outcome data in the sources patients usually need for medical decision-making. Many claims about fat loss, recovery, sleep, or muscle are based on physiology, animal work, or clinic practice patterns rather than large randomized human trials.

Potential safety concerns overlap with other growth hormone secretagogues: headache, water retention, tingling, hunger changes, glucose effects, and endocrine interactions 3, 8, 10. Because the evidence base is thinner, self-directed use from research-chemical vendors is especially risky; a licensed clinician and a state-regulated pharmacy matter.

What is tesamorelin, and why is its evidence different?

Tesamorelin, sold as Egrifta and Egrifta SV, is a growth hormone-releasing hormone analog with a specific FDA-approved use related to HIV-associated lipodystrophy. It has more indication-specific human evidence than the other peptides in this comparison 4, 5.

Clinical trial records include a completed phase 3 extension study of TH9507, the development name for tesamorelin, in patients with HIV-associated lipodystrophy; the ClinicalTrials.gov record lists 263 participants 5. A 2024 randomized trial also studied tesamorelin efficacy and safety in people with HIV on integrase inhibitors 4.

That evidence should not be generalized to everyone seeking weight loss, abdominal fat loss, bodybuilding, or longevity. HIV-associated lipodystrophy is a specific medical condition, and visceral adipose tissue outcomes in that population do not prove broad anti-aging or general weight-loss benefit.

Safety matters because tesamorelin and other growth hormone pathway agents can affect IGF-1 and glucose biology. Studies in metabolic disease show that IGF-1 and IGF-binding proteins relate to glycemia and disease severity, which is one reason lab review and follow-up are important when this pathway is being considered 3.

What is CJC-1295, and what is the difference between DAC and no-DAC forms?

CJC-1295 is a modified GHRH analog. CJC-1295 with DAC includes a Drug Affinity Complex, which binds albumin and extends action; CJC-1295 without DAC is commonly discussed as Modified GRF 1-29 and is shorter acting 1.

In a randomized trial in healthy adults, Teichman and colleagues studied CJC-1295 and found prolonged stimulation of growth hormone and IGF-1 secretion 1. This supports an endocrine effect, not a proven clinical outcome.

The key patient takeaway is CJC-1295 remains less clinically established than an approved, indication-specific therapy such as tesamorelin for HIV-associated lipodystrophy. Human data showing hormone-marker changes do not prove improved recovery, fat loss, muscle gain, sleep, or lifespan.

CJC-1295 safety questions include injection reactions, headache, flushing, swelling, numbness or tingling, glucose effects, and theoretical concerns with excess IGF-1 signaling 1, 3. People should avoid no-prescription sources that label products as “research only” for human use; our guide to peptides online explains why licensed access is different.

Which peptide has the strongest human evidence?

Tesamorelin has the strongest human evidence for a defined medical use: HIV-associated lipodystrophy with excess visceral adipose tissue. Sermorelin and CJC-1295 have human growth hormone or IGF-1 signal data, while ipamorelin is more often supported by mechanism and limited clinical evidence.

A useful rule: ask whether the evidence is a human outcome trial, a human hormone-marker study, an animal study, a cell study, or just a mechanism claim. For these peptides, human longevity and lifespan-extension evidence is not established.

Is sermorelin better than CJC-1295, ipamorelin, or tesamorelin?

There is no universal “best” peptide. The answer depends on the goal, the diagnosis, the quality of evidence for that goal, medical history, and whether the option can be accessed through a licensed clinician.

If the question is mechanism, sermorelin is a shorter GHRH-pathway signal, CJC-1295 is a modified GHRH analog with longer action when made with DAC, tesamorelin is a GHRH analog with indication-specific clinical evidence, and ipamorelin acts through the ghrelin receptor 1, 8.

If the question is evidence quality, tesamorelin is strongest for its studied HIV-lipodystrophy setting. CJC-1295 has a human randomized hormone-marker trial, sermorelin-related GHRH(1-29) has human GH-release evidence, and ipamorelin has less human outcome support in the sources available for this comparison 1, 2, 4.

If the question is access, Chia offers sermorelin through an online licensed-provider review and US 503A compounding pharmacy pathway. Chia does not offer CJC-1295, ipamorelin, or tesamorelin.

Can sermorelin, CJC-1295, and ipamorelin be taken together?

Combination protocols are discussed because GHRH-pathway peptides and ghrelin-receptor peptides act at different points in growth hormone signaling. But a plausible mechanism does not prove that a stack is better for fat loss, muscle gain, recovery, sleep, or longevity.

CJC-1295 plus ipamorelin is commonly combined in clinical and research practice because one signal acts through the GHRH receptor and the other through the ghrelin receptor. The safety caveat is that combination-specific human outcome trials are limited, and overlapping effects on glucose, swelling, headache, and IGF-1 need clinician oversight.

Sermorelin plus ipamorelin is discussed for the same reason: two different upstream signals may affect pituitary growth hormone pulses. The safety caveat is the same: no one should self-direct peptide stacking, especially with products sold online as “research only.” Our overview of what peptides are used for explains why medical context matters.

Sermorelin plus CJC-1295 is less straightforward because both are GHRH-pathway agents. Combining two agents in the same pathway may increase side effects without clear proof of better outcomes, so this is a clinician-level decision, not an internet protocol.

Sermorelin at Chia: clinician-reviewed peptide therapy online

At Chia, sermorelin is available in 3 forms: injection, nasal spray, and tablets. Treatment starts with a short online health questionnaire, then a licensed US provider reviews your history and prescribes only if clinically appropriate.

Chia medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to the patient’s door. Patients can message their care team through the patient portal between visits.

Sermorelin may also appear in Chia protocols when appropriate, including Foundation Longevity, which includes sermorelin injection, NAD+ injection, and glutathione injection, and Weight + Muscle, which includes sermorelin injection plus a choice of GLP-1. A provider determines whether any protocol fits your health history and goals.

What are the main risks and safety questions patients should know?

The biggest safety theme is endocrine monitoring. Growth hormone pathway drugs can affect IGF-1 and glucose biology, and clinical research has linked IGF-1 and IGF-binding proteins with glycemia and disease severity in metabolic disease settings 3.

• Glucose and insulin questions: people with diabetes, prediabetes, insulin resistance, or abnormal glucose control should review risks before using a growth hormone peptide 3, 10.
• Fluid and joint symptoms: swelling, stiffness, carpal-tunnel-like symptoms, or joint discomfort can occur with growth hormone pathway stimulation 10.
• Injection-site and general symptoms: redness, itching, headache, flushing, nausea, or dizziness should be discussed with a care team 1, 10.
• Cancer and pituitary history: active cancer, a history of cancer, pituitary tumors, or unexplained endocrine symptoms need careful review before considering this pathway 10.
• Pregnancy and breastfeeding: peptide therapy should be reviewed with a clinician, and many patients will not be eligible 10.

The licensed pathway matters. A clinician can review diagnoses, medications, labs, and follow-up needs. A state-licensed 503A pharmacy pathway is different from buying unlabeled or “research-only” peptides online for human use; our guide to USA peptides and research-only labels explains the difference.

What should you ask a provider before starting a growth hormone peptide?

Good questions protect you. They also help separate a real medical plan from a vague promise about energy, anti-aging, or body composition.

1. 1What diagnosis, symptom pattern, or health goal is this peptide being considered for?
2. 2Is there human evidence for this choice in people like me, or is the rationale mainly mechanism-based?
3. 3What labs should be checked before and during treatment, such as IGF-1, fasting glucose, A1c, or other endocrine markers?
4. 4Is this medication FDA-approved for my use, compounded, off-label, or investigational?
5. 5What side effects would mean I should message the care team or stop and seek urgent care?
6. 6What are the alternatives, including non-peptide options?

If you are comparing sermorelin with CJC-1295, ipamorelin, or tesamorelin, it may help to read our deeper guides on sermorelin and tesamorelin vs CJC-1295.

Frequently asked questions

Keep reading

Peptides

CJC-1295 No DAC Peptide: Modified GRF 1-29, Evidence, Risks, and Safer Questions to Ask

Peptides

Tesamorelin vs CJC-1295: Evidence, Uses, and Safety Differences

Peptides

CJC-1295 Ipamorelin vs Sermorelin: What Patients Should Know